SevoFlo

1. NAME OF VETERINARY THE MEDICINAL PRODUCT

SevoFlo 100% Inhalation vapour, liquid for dogs.

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Active substance:

Each bottle contains 250 ml sevoflurane (100%).

3. PHARMACEUTICAL FORM

Inhalation vapour, liquid.

4. CLINICAL PARTICULARS

4.1 Target species

Dogs.

4.2 Indications for use, specifying the target species

For the induction and maintenance of anaesthesia.

4.3 Contraindications

Do not use in dogs with known hypersensitivity to sevoflurane or other halogenated anaesthetic

agents.

Do not use in pregnant and lactating bitches (see section 4.7).

Do not use in dogs with a known or suspected genetic susceptibility to malignant hyperthermia.

Do not use in dogs less than 12 weeks of age.

4.4 Special warnings for each target species

None.

4.5 Special precautions for use

Special precautions for use in animals

Halogenated volatile anaesthetics can react with dry carbon dioxide (CO 2 ) absorbents to produce

carbon monoxide (CO) that may result in elevated levels of carboxyhaemoglobin in some dogs. In

order to minimise this reaction in rebreathing anaesthetic circuits, SevoFlo should not be passed

through soda lime or barium hydroxide that has been allowed to dry out.

The exothermic reaction that occurs between inhalation agents (including sevoflurane) and CO 2

absorbents is increased when the CO 2 absorbent becomes desiccated, such as after an extended period

of dry gas flow through the CO 2 absorbent canisters. Rare cases of excessive heat production, smoke

and/or fire in the anaesthetic machine have been reported during the use of a desiccated CO 2 absorbent

and sevoflurane. An unusual decrease in the expected depth of anaesthesia compared to the vaporiser

setting may indicate excessive heating of the CO 2 absorbent canister.

If it is suspected that the CO 2 absorbent may be desiccated, it must be replaced. The colour indicator

of most CO 2 absorbents does not necessarily change as a result of desiccation. Therefore, the lack of

significant colour change should not be taken as an assurance of adequate hydration. CO 2 absorbents

should be replaced routinely regardless of the state of the colour indicator.

2

1,1,3,3,3-pentafluoro-2-(fluoromethoxy)propene (C 4 H 2 F 6 O), also known as Compound A, is produced

when sevoflurane interacts with soda lime or barium hydroxide. Reaction with barium hydroxide

results in a greater production of Compound A than does the reaction with soda lime. Its concentration

in a circle absorber system increases with increasing sevoflurane concentrations and with decreasing

fresh gas flow rates. Sevoflurane degradation in soda lime has been shown to increase with

temperature. Since the reaction of carbon dioxide with absorbents is exothermic, this temperature

increase will be determined by the quantities of CO 2 absorbed, which in turn will depend on fresh gas

flow in the anaesthetic circle system, metabolic status of the dog and ventilation. Although Compound

A is a dose-dependent nephrotoxin in rats, the mechanism of this renal toxicity is unknown. Long-

duration, low-flow sevoflurane anaesthesia should be avoided due to the risks of Compound A

accumulation.

During maintenance of anaesthesia, increasing the concentration of sevoflurane produces a dose-

dependent decrease in blood pressure. Due to sevoflurane's low solubility in blood, these

haemodynamic changes may occur more rapidly than with other volatile anaesthetics. Arterial blood

pressure should be monitored at frequent intervals during sevoflurane anaesthesia. Facilities for

artificial ventilation, oxygen enrichment and circulatory resuscitation should be immediately available.

Excessive decreases in blood pressure or respiratory depression may be related to the depth of

anaesthesia and may be corrected by decreasing the inspired concentration of sevoflurane. The low

solubility of sevoflurane also facilitates rapid elimination by the lungs. The nephrotoxic potential of

certain NSAIDs, when used in the perioperative period, may be exacerbated by hypotensive episodes

during sevoflurane anaesthesia. In order to maintain renal blood flow, prolonged episodes of

hypotension (mean arterial pressure below 60 mmHg) should be avoided in dogs during sevoflurane

anaesthesia.

If malignant hyperthermia develops, the anaesthetic supply should be interrupted immediately and

100% oxygen administered using fresh anaesthetic hoses and a rebreathing bag. Appropriate

treatment should readily be instituted.

Compromised or debilitated dogs

Doses of sevoflurane may need adjustment for geriatric or debilitated dogs. Doses required for

maintenance anaesthesia may need to be reduced by approximately 0.5% in geriatric dogs (i.e. 2.8% to

3.1% in premedicated geriatric dogs and 3.2 to 3.3% in unpremedicated geriatric dogs). Limited

clinical experience in administering sevoflurane to dogs with renal, hepatic and cardiovascular

insufficiency suggests that sevoflurane may be safely used in these conditions. However, it is

recommended that such animals be monitored carefully during sevoflurane anaesthesia.

Sevoflurane may cause a small increase in intracranial pressure (ICP) under conditions of

normocapnia. In dogs with head injuries or other conditions placing them at risk from increased ICP, it

is recommended that hypocapnia be induced by means of controlled hyperventilation as a means of

preventing changes in ICP.

Special precautions to be taken by the person administering the veterinary medicinal product to

animals

In order to minimise exposure to sevoflurane vapour, the following recommendations are made:

 Use a cuffed endotracheal tube when possible for the administration of SevoFlo during

maintenance anaesthesia.

 Avoid using masking procedures for prolonged induction and maintenance of general

anaesthesia.

 Ensure that operating rooms and animal recovery areas are provided with adequate ventilation

or scavenging systems to prevent the accumulation of anaesthetic vapour.

 All scavenging/extraction systems must be adequately maintained.

 Pregnant and breast-feeding women should not have any contact with the product and should

avoid operating rooms and animal recovery areas.

 Care should be taken when dispensing SevoFlo, with immediate removal of any spillage.

 Do not inhale the vapour directly.

3

 Avoid contact by mouth.

 Halogenated anaesthetic agents may induce liver damage. This is an idiosyncratic response very

occasionally seen after repeated exposure.

 From an environmental point of view, it is considered good practice to use charcoal filters with

scavenging equipment.

Direct exposure to eyes may result in mild irritation. If eye exposure occurs, the eye should be flushed

with plenty of water for 15 minutes. Medical attention should be sought if irritation persists.

In case of accidental contact with the skin, wash affected area with abundant water.

Symptoms of human overexposure (inhalation) to sevoflurane vapour include respiratory depression,

hypotension, bradycardia, shivering, nausea and headache. If these symptoms occur, the individual

should be removed from the source of exposure and medical attention sought.

Advice to doctors: Maintain a patent airway and give symptomatic and supportive treatment.

4.6 Adverse reactions (frequency and seriousness)

The most frequently reported adverse reactions associated with SevoFlo administration were

hypotension, followed by tachypnoea, muscle tenseness, excitation, apnoea, muscle fasciculations and

emesis.

Sevoflurane causes dose-dependant respiratory depression, therefore respiration should be closely

monitored during sevoflurane anaesthesia and the inspired concentration of sevoflurane adjusted

accordingly.

The use of some anaesthetic regimens that include sevoflurane may result in bradycardia that is

reversible with anticholinergics.

Infrequent adverse reactions include paddling, retching, salivation, cyanosis, premature ventricular

contractions and excessive cardiopulmonary depression.

Transient elevations in aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate

dehydrogenase (LDH), bilirubin and white blood cell counts may occur with sevoflurane, as with the

use of other halogenated anaesthetic agents.

Hypotension during sevoflurane anaesthesia may result in decreased renal blood flow.

The possibility of sevoflurane triggering episodes of malignant hyperthermia in susceptible dogs

cannot be ruled out.

4.7 Use during pregnancy or lactation

Do not use during pregnancy and lactation because the safety of the veterinary medicinal product has

not been established during pregnancy and lactation. However, there is limited clinical experience of

the use of sevoflurane, after propofol induction, in bitches undergoing caesarean section, without any

ill effects being detected in either the bitch or the puppies. Use only according to the risk/benefit

assessment of the responsible veterinarian.

4

4.8 Interaction with other medicinal products and other forms of interaction

Intravenous Anaesthetics:

Sevoflurane administration is compatible with the intravenous barbiturates and propofol. The

concurrent administration of thiopental, however, may slightly increase sensitivity to adrenaline-

induced cardiac arrhythmias.

Benzodiazepines and Opioids:

Sevoflurane administration is compatible with benzodiazepines and opioids commonly used in

veterinary practice. In common with other inhalational anaesthetics, the MAC of sevoflurane is

reduced by the concurrent administration of benzodiazepines and opioids.

Phenothiazines and alpha-2-agonists:

Sevoflurane is compatible with phenothiazines and alpha-2-agonists commonly used in veterinary

practice. Αlpha-2-agonists have an anaesthetic sparing effect and therefore the dose of sevoflurane

should be reduced accordingly. Limited data are available on the effects of the highly potent alpha-2-

agonists (medetomidine and romifidine) as premedication. Therefore they should be used with caution.

Bradycardia may develop when alpha-2-agonists are used with sevoflurane. Bradycardia can be

reversed by the administration of anticholinergics.

Anticholinergics:

Studies using sevoflurane anaesthetic protocols that included atropine or glycopyrrolate as

premedicants showed these anticholinergics to be compatible with sevoflurane in dogs.

In a laboratory study, the use of an acepromazine/oxymorphone/thiopental/sevoflurane anaesthetic

regimen resulted in prolonged recoveries in all the dogs treated, compared to recoveries in dogs

anaesthetised with sevoflurane alone.

The use of sevoflurane with nondepolarising muscle relaxants has not been evaluated in dogs.

However, in humans the use of sevoflurane increases both the intensity and duration of neuromuscular

blockade induced by nondepolarising muscle relaxants.

4.9 Amounts to be administered and administration route

Inspired Concentration:

SevoFlo should be administered via a vaporiser specifically calibrated for use with sevoflurane so that

the concentration delivered can be accurately controlled. SevoFlo contains no stabiliser and does not

affect the calibration or operation of these vaporisers in any way. The administration of sevoflurane

must be individualised based on the dog's response.

Premedication:

The necessity for and choice of premedication is left to the discretion of the veterinarian.

Preanaesthetic doses for premedicants may be lower than the label directions for their use as a single

medication.

Induction of anaesthesia:

For mask induction using sevoflurane, inspired concentrations of 5 to 7% sevoflurane with oxygen are

employed to induce surgical anaesthesia in the healthy dog. These concentrations can be expected to

produce surgical anaesthesia within 3 to 14 minutes and may be set initially, or may be achieved

gradually over the course of 1 to 2 minutes. The use of premedicants does not affect the concentration

of sevoflurane required for induction.

Maintenance of anaesthesia:

Sevoflurane may be used for maintenance anaesthesia following mask induction with sevoflurane or

following induction with injectable agents. The concentration of sevoflurane necessary to maintain

anaesthesia is less than that required for induction.

5

Surgical levels of anaesthesia in the healthy dog may be maintained with inhaled concentrations of 3.3

to 3.6% in the presence of premedication. In the absence of premedication, inhaled concentrations of

sevoflurane in the range 3.7 to 3.8% will provide surgical levels of anaesthesia in the healthy dog.

The presence of surgical stimulation may require an increase in the concentration of sevoflurane. The

use of injectable induction agents without premedication has little effect on the concentrations of

sevoflurane required for maintenance. Anaesthetic regimens that include opioid, alpha-2-agonist,

benzodiazepine or phenothiazine premedication will allow the use of lower sevoflurane maintenance

concentrations.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

SevoFlo overdose may result in profound respiratory depression. Therefore, respiration must be

monitored closely and supported when necessary with supplementary oxygen and/or assisted

ventilation.

In cases of severe cardiopulmonary depression, administration of sevoflurane should be discontinued,

the existence of a patent airway ensured, and assisted or controlled ventilation with pure oxygen

initiated. Cardiovascular depression should be treated with plasma expanders, pressor agents,

antiarrhythmic agents or other appropriate techniques.

Due to sevoflurane's low solubility in blood, increasing the concentration may result in rapid

haemodynamic changes (dose-dependent decreases in blood pressure) compared to other volatile

anaesthetics . Excessive decreases in blood pressure or respiratory depression may be corrected by

decreasing or discontinuing the inspired concentration of sevoflurane.

4.11 Withdrawal period(s)

Not applicable.

5. PHARMACOLOGICAL PROPERTIES

Pharmacotherapeutic group: inhalation anaesthetic, ATCvet code: QN 01AB08

5.1 Pharmacodynamic properties

Sevoflurane is an inhalational anaesthetic agent, having a light odour, for induction and maintenance

of general anaesthesia. The Minimum Alveolar Concentration (MAC) of sevoflurane in dogs is 2.36%.

Multiples of MAC are used as a guide for surgical levels of anaesthesia, which are typically 1.3 to 1.5

times the MAC value.

Sevoflurane produces unconsciousness by its action on the central nervous system. Sevoflurane

produces only modest increases in cerebral blood flow and metabolic rate, and has little or no ability to

potentiate seizures. Sevoflurane may increase intracranial pressure at concentrations of 2.0 MAC and

above under normal partial pressures of carbon dioxide (normocapnia), but intracranial pressure has

been shown to remain within normal range at sevoflurane concentrations of up to 1.5 MAC if

hypocapnia is induced by hyperventilation.

Sevoflurane has a variable effect on heart rate, which tends to increase from baseline at low MAC and

fall back with increasing MAC. Sevoflurane causes systemic vasodilation and produces dose-

dependent decreases in mean arterial pressure, total peripheral resistance, cardiac output and possibly

the strength of myocardial contraction and speed of myocardial relaxation.

Sevoflurane has a depressive effect on respiration characterised by a fall in ventilation frequency.

Respiratory depression may lead to respiratory acidosis and respiratory arrest (at sevoflurane

concentrations of 2.0 MAC and above) in spontaneously breathing dogs.

6

Concentrations of sevoflurane below 2.0 MAC result in a small net increase in total liver blood flow.

Hepatic oxygen delivery and consumption were not significantly altered at concentrations up to 2.0

MAC.

Sevoflurane administration adversely affects the autoregulation of renal blood flow in dogs. As a

result, renal blood flow falls in a linear fashion with increasing hypotension in sevoflurane

anaesthetised dogs. Nevertheless, renal oxygen consumption, and hence renal function, are preserved

at mean arterial pressures above 40 mmHg.

5.2 Pharmacokinetic particulars

A minimal amount of sevoflurane is required to be dissolved in the blood before the alveolar partial

pressure is in equilibrium with the arterial partial pressure because of the low solubility of sevoflurane

in blood (blood/gas partition coefficient at 30°C is 0.63 to 0.69). During sevoflurane induction, there

is a rapid increase in alveolar concentration towards the inspired concentration, with the ratio of

inspired to end-tidal concentration of sevoflurane reaching a value of 1 within 10 minutes. Anaesthetic

induction is correspondingly rapid and the depth of anaesthesia changes rapidly with changes in

anaesthetic concentration.

Sevoflurane is metabolised to a limited extent in the dog (1 to 5%). The principle metabolites are

hexafluoroisopropanol (HFIP) with release of inorganic fluoride and CO 2 . Fluoride ion concentrations

are influenced by the duration of anaesthesia and the concentration of sevoflurane. Once formed, HFIP

is rapidly conjugated with glucuronic acid and eliminated as a urinary metabolite. No other metabolic

pathways for sevoflurane have been identified. In dogs exposed to 4% sevoflurane for 3 hours, mean

peak maximum serum fluoride concentrations of 20.0  4.8 mol/l have been observed after 3 hours of

anaesthesia. Serum fluoride fell quickly after anaesthesia ended and had returned to baseline by 24

hours post-anaesthesia.

The elimination of sevoflurane is biphasic in nature, with an initial rapid phase and a second, slower

phase. Parent compound (the dominant fraction) is eliminated via the lungs. The half-life for the slow

elimination phase is approximately 50 minutes. Elimination from blood is largely complete within 24

hours. The elimination time from adipose tissue is more prolonged than from the brain.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

None.

6.2 Incompatibilities

None known.

6.3 Shelf life

Shelf-life of the veterinary medicinal product as packaged for sale: 3 years

6.4 Special precautions for storage

Do not store above 25C.

Do not refrigerate.

Keep the bottle tightly closed.

7

6.5 Nature and composition of immediate packaging

SevoFlo is presented in a cardboard box containing a 250 ml polyethylene naphthalate (PEN) bottle

with a Quik-Fil closure.

6.6 Special precautions for the disposal of unused veterinary medicinal product or waste

materials derived from the use of such products

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal

products should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

Abbott Laboratories Ltd

Abbott House

Vanwall Business Park

Vanwall Road

Maidenhead

Berkshire SL6 4XE

United Kingdom

8. MARKETING AUTHORISATION NUMBER(S)

EU/2/02/035/007

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 11 December 2002

Date of last renewal: 6 November 2007

10. DATE OF REVISION OF THE TEXT

28/07/2010

Detailed information on this veterinary medicinal product is available on the website of the European

Medicines Agency (EMA) http://www.ema.europa.eu / .

PROHIBITION OF SALE, SUPPLY AND/OR USE

Not applicable.

8

ANNEX II

A.

MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR

BATCH RELEASE

B.

CONDITIONS OR RESTRICTIONS OF THE MARKETING

AUTHORISATION REGARDING SUPPLY OR USE

C.

CONDITIONS OR RESTRICTIONS OF THE MARKETING

AUTHORISATION WITH REGARD TO SAFE AND EFFECTIVE USE

D.

STATEMENT OF THE MRLs

9

A. MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH

RELEASE

Name and address of the manufacturer(s) responsible for batch release

Aesica Queenborough Limited

Queenborough

Kent

ME11 5EL

United Kingdom

B. CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION

REGARDING SUPPLY OR USE

To be supplied only on veterinary prescription.

C. CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION WITH

REGARD TO THE SAFE AND EFFECTIVE USE OF THE PRODUCT

Not applicable.

D. STATEMENT OF THE MRLs

Not applicable.

10

ANNEX III

LABELLING AND PACKAGE LEAFLET

11

A. LABELLING

12

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

CARTON BOX

1. NAME OF VETERINARY THE MEDICINAL PRODUCT

SevoFlo 100% Inhalation vapour, liquid for dogs.

sevoflurane

2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES

100% sevoflurane

3. PHARMACEUTICAL FORM

Inhalation vapour, liquid

4. PACKAGE SIZE

250 ml

5. TARGET SPECIES

Dogs

6. INDICATION(S)

For induction and maintenance of anaesthesia.

7. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use. Administer by inhalation using a vaporiser calibrated for

sevoflurane.

8. WITHDRAWAL PERIOD

Not applicable.

9. SPECIAL WARNING(S), IF NECESSARY

Do not use in dogs with known hypersensitivity to sevoflurane or other halogenated anaesthetic

agents.

Do not use in pregnant and lactating bitches.

Do not use in dogs with a known or suspected genetic susceptibility to malignant hyperthermia.

13

Do not use in dogs less than 12 weeks of age.

For operator warnings - read the package leaflet before use.

10. EXPIRY DATE

EXP {month/year}

11. SPECIAL STORAGE CONDITIONS

Do not store above 25°C.

Do not refrigerate.

Keep the bottle tightly closed.

12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR

WASTE MATERIALS, IF ANY

Any unused veterinary medicinal product or waste materials derived from the veterinary medicinal

product should be disposed of in accordance with local regulations.

13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR

RESTRICTIONS REGARDING SUPPLY AND USE, if applicable

For animal treatment only - to be supplied only on veterinary prescription.

14. THE WORDS “KEEP OUT OF THE REACH AND SIGHT OF CHILDREN”

Keep out of the reach and sight of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Abbott Laboratories Ltd

Abbott House

Vanwall Business Park

Vanwall Road

Maidenhead

Berkshire SL6 4XE

United Kingdom

16. MARKETING AUTHORISATION NUMBER(S)

EU/2/02/035/007

17. MANUFACTURER’S BATCH NUMBER

Lot {number}

14

PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE

BOTTLE

1. NAME OF VETERINARY THE MEDICINAL PRODUCT

SevoFlo 100% Inhalation vapour, liquid for dogs.

sevoflurane

2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES

100% sevoflurane

3. PHARMACEUTICAL FORM

Inhalation vapour, liquid

4. PACKAGE SIZE

250 ml

5. TARGET SPECIES

Dogs

6. INDICATION(S)

For induction and maintenance of anaesthesia.

7. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.

8. WITHDRAWAL PERIOD

Not applicable

9. SPECIAL WARNING(S), IF NECESSARY

Do not use in pregnant and lactating bitches or in dogs less than 12 weeks of age.

For operator warnings – read the package leaflet before use.

15

10. EXPIRY DATE

EXP {month/year}

11. SPECIAL STORAGE CONDITIONS

Do not store above 25°C.

Do not refrigerate.

Keep the bottle tightly closed.

12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR

WASTE MATERIALS, IF ANY

13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR

RESTRICTIONS REGARDING SUPPLY AND USE, if applicable

For animal treatment only - to be supplied only on veterinary prescription.

14. THE WORDS “KEEP OUT OF THE REACH AND SIGHT OF CHILDREN”

Keep out of the reach and sight of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Abbott Laboratories Ltd

Abbott House

Vanwall Business Park

Vanwall Road

Maidenhead

Berkshire SL6 4XE

United Kingdom

16. MARKETING AUTHORISATION NUMBER(S)

EU/2/02/035/007

17. MANUFACTURER’S BATCH NUMBER

Lot {number}

16

B. PACKAGE LEAFLET

17

PACKAGE LEAFLET

SevoFlo

Inhalation vapour, liquid for dogs, 100% sevoflurane

1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF

THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH

RELEASE, IF DIFFERENT

Marketing authorisation holder

Abbott Laboratories Ltd

Abbott House

Vanwall Business Park

Vanwall Road

Maidenhead

Berkshire SL6 4XE

United Kingdom

Manufacturer for batch release

Aesica Queenborough Limited

Queenborough

Kent

ME11 5EL

United Kingdom

2. NAME OF VETERINARY THE MEDICINAL PRODUCT

SevoFlo 100% Inhalation vapour, liquid for dogs.

sevoflurane

3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)

100% sevoflurane

4. INDICATION(S)

For the induction and maintenance of anaesthesia.

5. CONTRAINDICATIONS

Do not use in dogs with known hypersensitivity to sevoflurane or other halogenated anaesthetic

agents.

Do not use in pregnant and lactating bitches (see section 12).

Do not use in dogs with a known or suspected genetic susceptibility to malignant hyperthermia.

Do not use in dogs less than 12 weeks of age.

18

6. ADVERSE REACTIONS

The most frequently reported adverse reactions associated with SevoFlo administration were

hypotension, followed by tachypnoea, muscle tenseness, excitation, apnoea, muscle fasciculations and

emesis.

Sevoflurane causes dose-dependant respiratory depression, therefore respiration should be closely

monitored during sevoflurane anaesthesia and the inspired concentration of sevoflurane adjusted

accordingly.

The use of some anaesthetic regimens that include sevoflurane may result in bradycardia that is

reversible with anticholinergics.

Infrequent adverse reactions include paddling, retching, salivation, cyanosis, premature ventricular

contractions and excessive cardiopulmonary depression.

Transient elevations in aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate

dehydrogenase (LDH), bilirubin and white blood cell count may occur with sevoflurane, as with the

use of other halogenated anaesthetic agents.

Hypotension during sevoflurane anaesthesia may result in decreased renal blood flow.

The possibility of sevoflurane triggering episodes of malignant hyperthermia in susceptible dogs

cannot be ruled out.

If any serious effects or other effects not mentioned in this leaflet are noticed, please ensure the

veterinary surgeon is informed.

7. TARGET SPECIES

Dogs.

8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

Inspired Concentration:

SevoFlo should be administered via a vaporiser specifically calibrated for use with sevoflurane so that

the concentration delivered can be accurately controlled. SevoFlo contains no stabiliser and does not

affect the calibration or operation of these vaporisers in any way. The administration of sevoflurane

must be individualised based on the dog's response.

Premedication:

The necessity for and choice of premedication is left to the discretion of the veterinarian.

Preanaesthetic doses for premedicants may be lower than the label directions for their use as a single

medication.

Induction of anaesthesia:

For mask induction using sevoflurane, inspired concentrations of 5 to 7% sevoflurane with oxygen are

employed to induce surgical anaesthesia in the healthy dog. These concentrations can be expected to

produce surgical anaesthesia in 3 to 14 minutes and may be set initially, or may be achieved gradually

over the course of 1 to 2 minutes. The use of premedicants does not affect the concentration of

sevoflurane required for induction.

Maintenance of anaesthesia:

19

Sevoflurane may be used for maintenance anaesthesia following mask induction using sevoflurane or

following induction with injectable agents. The concentration of sevoflurane necessary to maintain

anaesthesia is much less than that required for induction.

Surgical levels of anaesthesia in the healthy dog may be maintained with inhaled concentrations of 3.3

to 3.6% in the presence of premedication. In the absence of premedication, inhaled concentrations of

sevoflurane in the range of 3.7 to 3.8% will provide surgical levels of anaesthesia in the healthy dog.

The presence of surgical stimulation may require an increase in the concentration of sevoflurane. The

use of injectable induction agents without premedication has little effect on the concentrations of

sevoflurane required for maintenance. Anaesthetic regimens that include opioid, alpha-2-agonist,

benzodiazepine or phenothiazine premedication will allow the use of lower sevoflurane maintenance

concentrations.

9.

ADVICE ON CORRECT ADMINISTRATION

For inhalation use only, using a suitable carrier gas. SevoFlo should be administered via a vaporiser

specifically calibrated for use with sevoflurane so that the concentration delivered can be accurately

controlled. SevoFlo contains no stabiliser and does not affect the calibration or operation of these

vaporisers.

The administration of general anaesthesia must be individualised based on the dog's response.

Interaction with other veterinary medicinal products and other forms of interaction

Intravenous Anaesthetics:

Sevoflurane administration is compatible with the intravenous barbiturates and propofol. The

concurrent administration of thiopental, however, may slightly increase sensitivity to adrenaline-

induced cardiac arrhythmias.

Benzodiazepines and Opioids:

Sevoflurane administration is compatible with benzodiazepines and opioids commonly used in

veterinary practice. In common with other inhalational anaesthetics, the minimum alveolar

concentration (MAC) of sevoflurane is reduced by the concurrent administration of benzodiazepines

and opioids.

Phenothiazines and alpha-2-agonists:

Sevoflurane is compatible with phenothiazines and alpha-2-agonists commonly used in veterinary

practice. Αlpha-2-agonists have an anaesthetic sparing effect and therefore the dose of sevoflurane

should be reduced accordingly. Limited data are available on the effects of the highly potent alpha-2-

agonists (medetomidine and romifidine) as premedication. Therefore they should be used with caution.

Bradycardia may develop when alpha-2-agonists are used with sevoflurane. Bradycardia can be

reversed by the administration of anticholinergics.

Anticholinergics:

Studies using sevoflurane anaesthetic protocols that included atropine or glycopyrrolate as

premedicants showed these anticholinergics to be compatible with sevoflurane in dogs.

In a laboratory study, the use of an acepromazine/oxymorphone/thiopental/sevoflurane anaesthetic

regimen resulted in prolonged recoveries in all the dogs treated, compared to recoveries in dogs

anaesthetised with sevoflurane alone.

The use of sevoflurane with nondepolarising muscle relaxants has not been evaluated in dogs.

However, in humans the use of sevoflurane increases both the intensity and duration of neuromuscular

blockade induced by nondepolarising muscle relaxants.

20

10. WITHDRAWAL PERIOD

Not applicable.

11. SPECIAL STORAGE PRECAUTIONS

Keep out of the reach and sight of children.

Do not store above 25°C.

Do not refrigerate.

Keep the bottle tightly closed.

Do not use after the expiry date stated on the label.

12. SPECIAL WARNING(S)

Special precautions for use:

Halogenated volatile anaesthetics can react with desiccated carbon dioxide (CO 2 ) absorbents to

produce carbon monoxide (CO) that may result in elevated levels of carboxyhaemoglobin in some

dogs. In order to minimise this reaction in rebreathing anaesthetic circuits, SevoFlo should not be

passed through soda lime or barium hydroxide that has been allowed to dry out.

The exothermic reaction that occurs between sevoflurane and CO 2 absorbents is increased when the

CO 2 absorbent becomes desiccated (dried out), such as after an extended period of dry gas flow

through the CO 2 absorbent canisters. Rare cases of excessive heat production, smoke and/or fire in the

anaesthetic machine have been reported during the use of a desiccated CO 2 absorbent and sevoflurane.

An unusual decrease in the expected depth of anaesthesia compared to the vaporiser setting may

indicate excessive heating of the CO 2 absorbent canister.